PMI-58

      Philip Morris International’s aerosol chemistry list of 58 constituents

      Cigarette smoke is a very complex mixture in which more than 6000 constituents have been identified. Within this complex mixture, about 100 constituents have been associated with smoking-related disease in smokers by public health authorities. The World Health Organization (WHO), the U.S. Food and Drug Administration (FDA) and Health Canada (HC) have independent requirements for analyzing and reporting on some of these constituents. At PMI, we routinely monitor the levels of these constituents in standardized settings and we aim to reduce and, if possible, completely eliminate their presence in the aerosol of our smoke-free products.

      Among more than 6000 constituents (Rodgman and Perfetti, 2013), several harmful and potentially harmful constituents (HPHCs) have been associated with the causation of disease in smokers, such as aromatic amines (Bartsch et al., 1993; Vineis and Pirastu, 1997), gas-phase constituents (Costa et al., 1986; Penn and Snyder, 1996; Witschi et al., 1997), oxygen-free radicals (Pryor, 1997; Valavanidis et al., 2009), polycyclic aromatic hydrocarbons (PAHs) (Penn et al., 1981; Smith et al., 2000), and tobacco-specific N-nitrosamines (TSNAs) (Hecht, 1998, 1999). However, a causal link between a specific smoke constituent and disease has not been conclusively established.

      Since it is not possible to quantify all constituents present in cigarette smoke, various priority lists of smoke toxicants in mainstream cigarette smoke have been proposed for the evaluation of commercial market cigarettes based mainly on risk assessments (Cunningham et al., 2011; Fowles and Dybing, 2003; Haussmann, 2012; Hecht, 2006; Hoffmann et al., 1997; Pankow et al., 2007; Rodgman and Green, 2003; Smith and Hansch, 2000; Talhout et al., 2011; Vorhees and Dodson, 1999; Xie et al., 2012).

       

      Smoke constituent reporting

      Smoke constituent reporting and brand-by-brand disclosure is required by different regulatory authorities, either on an annual basis (Health Canada, British Columbia, Brazil, and Taiwan) or as a one-off disclosure (Massachusetts Department of Health, UK, and Australia) (Wright, 2015). The lists of smoke constituents to be reported show a great deal of similarity between different regulatory authorities (Table 1); however, with the exception of Health Canada (Health Canada, 2000), specific test methods have not been defined or validated.  

       

      Philip Morris International’s aerosol chemistry list of 58 constituents

      The list of constituents measured in the evaluation of the mainstream aerosol composition of PMI's Tobacco Heating System (THS) is presented in Table 1 and compared to lists of priority smoke constituents proposed by the WHO Study Group on Tobacco Product Regulation (TobReg) (WHO, 2007; WHO, 2008; WHO, 2015), Health Canada (Health Canada, 2000), and the FDA (U.S. FDA, 2012a and b). The list of 58 constituents (‘PMI-58 list’) covers smoke constituents determined by the International Organization for Standardization (ISO) standard methods (carbon monoxide [CO], nicotine, nicotine-free dry particulate mattter [NFDPM], total particulate matter [TPM], and water) and chemical constituent representatives of all major toxicologically relevant chemical classes of compounds present in both the particulate phase and gas/vapor phase of cigarette smoke and was originally based on recommendations by the U.S. Consumer Product Safety Commission on smoke constituents presenting toxicological concerns in low ignition-potential cigarettes (US CPSC, 1993) and compounds reported in cigarette smoke which have been classified as either known or probable human carcinogens by the International Agency for Research on Cancer (IARC, 1985). Further additional HPHCs identified in mainstream cigarette smoke were considered and, if deemed relevant, included in the PMI-58 list of constituents requiring measurement for product evaluation. The PMI-58 list contains all constituents required for reporting by different regulatory authorities including the HPHCs which are subject to reporting on the FDA’s abbreviated list (U.S. FDA, 2012b), Health Canada (Health Canada, 2000), and all smoke constituents identified as priority toxicants and proposed for reporting by TobReg (WHO, 2007; WHO 2008; WHO, 2015).

       

      Collection of aerosol for HPHC measurements

      All machine-smoking methods have their limitations (Borgerding and Klus, 2005; Dixon and Borgerding, 2006; Roemer and Carchman, 2011), particularly the inability to reflect the variation in human puffing patterns and exposure to smoke constituents (Hammond et al., 2007; Stratton et al., 2001). Compared to the ISO 3308 machine-smoking regimen (ISO, 1991), the more intense machine-smoking regimen proposed by Health Canada (2000) results in much higher aerosol constituent yields which are thought to more closely represent smoker exposure to smoke constituents (Hammond et al., 2007; Hammond and O’Connor, 2008). No single machine-smoking regimen can represent all human smoking behavior (Stratton et al., 2001); however, machine-smoking testing is useful for characterizing tobacco product emissions for design and regulatory purposes. Data on emissions from machine measurements may also be useful as inputs for product hazard assessment, but smoking machine-derived data are not intended to be, nor are they valid as, measures of human exposure or risks (Hatsukami et al., 2012; WHO, 2012).

      More information on the development of constituent lists

      The World Health Organization (WHO) Study Group on Tobacco Product Regulation (TobReg), composed of leading public health experts and scientists, has proposed a scientific basis for tobacco product regulation (WHO, 2007). As part of their recommendation, this group concluded that chemical measurements of smoke constituents determined by a smoking machine is probably the most effective approach currently available for scientifically assessing differences between products for regulatory assessment of product toxicity (Burns et al., 2008). However, evaluating tobacco products using machine-measured “tar” (or using ISO 4387 terminology, Nicotine-Free Dry Particulate Matter, NFDPM), nicotine, and carbon monoxide (CO) yields may be misleading to smokers. It was concluded that the Health Canada Intense (HCI) machine-smoking protocol (55 mL puff volume, 30 seconds puff interval, 2 seconds puff, 100% vent blocking, butt length 23 mm for non-filter cigarettes or the length of filter overwrap plus 3 mm for filter brands) (Health Canada, 2000) offered significant advantages over the International Organization for Standardization (ISO)/Federal Trade Commission (FTC) standard machine-smoking regimen (35 mL puff volume, 60 second puff interval, 2 second puff, no vent blocking) (ISO: ISO, 1991; FTC: Federal Trade Commission, 1967).  Cigarettes should be collected and sampled according to ISO 8243 (ISO, 2006) and conditioned prior to machine-smoking for at least 48 hours at 22 ± 1 ᵒC and a relative humidity of 60 ± 3% according to ISO 3402 (ISO, 1999). Using the HCI machine-smoking protocol, it was recommended that manufacturers of tobacco products report to the Member States of the WHO Framework Convention on Tobacco Control (FCTC) the yields of a priority list of 25 smoke constituents in mainstream smoke (Table 1) expressed on a per milligram (mg) NFDPM basis. Furthermore, it was proposed to regulate the presence of two TSNAs, namely N-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) based on ceilings of 114 ng and 72 ng normalized per mg nicotine in smoke, respectively. Normalizing the levels of NNK and NNN per mg nicotine was considered to reduce the misleading differences between the levels of both constituents when expressed on a per cigarette basis (Hammond et al., 2007). 

      In 2008, TobReg (WHO, 2008) reduced the previous priority list from 25 to 18 toxicants in mainstream smoke and proposed that 9 priority toxicants (1,3-butadiene, acetaldehyde, acrolein, benzene, benzo[a]pyrene, CO, formaldehyde, NNK, and NNN) should be mandated for lowering and regulation (Table 1). TobReg recommended setting ceilings based on mg of nicotine for each of these priority toxicants defined for  mandated reduction to be based on the market median for NNN ad NNK and 125% of the median for the remaining constituents. To determine limits, TobReg proposed to apply ISO 8243 for sampling and the HCI smoking regimen for smoking collection. The most important criterion for the selection of priority compounds for regulation was evidence of toxicity (Fowles and Dybing, 2003). It was proposed that cigarette samples should be obtained as part of a series of at least five sub-periods from either manufacturers/importers or from retail locations according to the ISO standard method 8243 for sampling of cigarettes (ISO, 2006). The ISO standard method 3402 for conditioning of cigarettes prior to smoking (ISO, 1999) and the HCI machine-smoking regimen (Health Canada, 2000) were proposed. It was also proposed that nicotine and CO yields should be determined by ISO standard methods 10315 and 8454, respectively (ISO, 2000, ISO 2007), while other toxicants should be determined by official methods recommended by Health Canada (2000) and expressed on a per mg nicotine basis. 

      The FDA has established a list of 93 HPHCs in tobacco products and tobacco smoke (U.S. FDA, 2012a) and issued draft guidance on the reporting of an abbreviated list of 18 HPHCs in mainstream cigarette smoke and 9 HPHCs in smokeless tobacco products for which analytical protocols are well established and widely available (U.S. FDA, 2012b). The protocols recommend machine-smoking of cigarettes to be performed using both the ISO and HCI regimens (ISO, 1991; Health Canada, 2000) and seven replicates used for the determination of all HPHCs, except nicotine and CO where 20 replicates are recommended. HPHC quantities should be expressed on a per cigarette basis and reported by tobacco product manufacturers to the FDA. In addition, the FDA has encouraged tobacco product manufacturers to include HPHC data in new product applications.

      In 2015, TobReg identified 39 priority toxicants in mainstream cigarette smoke (WHO, 2015). The list of 39 priority toxicants was based primarily on lists of toxicants previously identified by Health Canada (Health Canada, 2000), the National Institute for Public Health and the Environment in the Netherlands (Talhout et al., 2011), and the U.S. Food and Drug Administration (U.S. FDA, 2012). Previous recommendations for standard cigarettes were extended to cover other smoked tobacco products, such as non-standard cigarettes (e.g., ‘slims’), cigars, water pipes, roll-your-own and low ignition-propensity cigarettes. However, specific recommendations on machine-smoking regimens for these products were not detailed. It was, however, recommended that standardized testing methods validated by the WHO Tobacco Laboratory Network (TobLabNet), a global network of government, academic and independent laboratories should be used. At present, TobLabNet has validated methods for the determination of B(a)P, CO, nicotine, volatile organic compounds, aldehydes, and TSNAs (N-nitrosoanabasine, N-nitrosoanatabine, NNK, and NNN) in mainstream smoke, while a method for the determination of ammonia is in progress. TobReg also concluded that the same principles used to set upper limits of emissions to toxicants in foods and other consumer products should be applied to tobacco products and that “tar” need not be determined as it is not a sound basis for regulation.

      Bartsch, H., Malaveille, C., Friesen, M., Kadlubar, F.F., and Vineis, P. 1993. Black (air-cured) and blond (flue-cured) tobacco cancer risk. IV: Molecular dosimetry studies implicate aromatic amines as bladder carcinogens. Eur. J. Cancer 29A(8), 1199-1207.

      Borgerding, M., and Klus, H. 2005. Analysis of complex mixtures – Cigarette smoke. Exp. Toxicol. Pathol. 57(Suppl. 1), 43-73.

      Borgerding, M.F., Bodnar, J.A., and Wingate, D.E. 2000. The 1999 Massachusetts Benchmark Study – Final Report, July 24. Available at: https://www.industrydocuments.ucsf.edu/tobacco/docs/#id=rfdx0057 (Accessed 28.02.2023).

      Burns, D.M., Dybing, E., Gray, N., Hecht, S., Anderson, C., Sanner, T., O’Connor, R., Djordjevic, M., Dresler, C., Hainaut, P., Jarvis, M., Opperhuizen, A., and Straif, K. 2008. Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organization TobReg proposal. Tob. Control 17(2), 132-141.

      Costa, D.L., Kutzman, R.S., Lehmann, J.R., and Drew, R.T. 1986. Altered lung function and structure in the rat after subchronic exposure to acrolein. Am. Rev. Respir. Dis. 133(2), 286-291.

      Cunningham, F.H., Fielbelkorn, S., Johnson, M., and Meridith, C. 2011. A novel application of the Margin of Exposure approach: Segregation of tobacco smoke toxicants. Food Chem. Toxicol. 49(11), 2921-2933.

      Dixon, M., and Borgerding, M. F. 2006. Recent advantages in the application and understanding of alternative smoking regimes. Recent Adv. Tob. Sci. 32, 3-84.

      Federal Trade Commission. 1967. Cigarettes: Testing for tar and nicotine content. Federal Register 32(147), 11178.

      Fowles, J., and Dybing, E. 2003. Application of toxicological risk assessment principles to the chemical constituents of cigarette smoke. Tob. Control 12(4), 424-430.

      Hammond, D., and O’Connor, R.J. 2008. Constituents in tobacco and smoke emissions from Canadian cigarettes. Tob. Control 17(Suppl. 1), i24-i31.

      Hammond, D., Wiebel, F., Kozlowski, L.T., Borland, R. Cummings, K.M., O’Connor, R.J., McNeill, A., Connolly, G.N., Arnott, D., and Fong, G.T. 2007. Revising the machine smoking regime for cigarette emissions: implication for tobacco control policy. Tob. Control 16(1), 8-14.

      Hatsukami, D.K., Biener, L., Leischow, S.J., and Zeller, M.R. 2012. Tobacco and nicotine product testing. Nicotine Tob. Res. 14(1), 7-17.

      Haussmann, H.J. 2012. Use of hazard indices for a theoretical evaluation of cigarette smoke composition. Chem. Res. Toxicol. 25(4), 794-810.

      Health Canada. 2000. Tobacco reporting regulations. Available here (accessed 28.02.2023).

      Hecht, S.S. 1998. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol. 11(6), 559-603.

      Hecht, S.S. 1999. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 91(14), 1194-1210.

      Hecht, S.S. 2006. Cigarette smoking: cancer risks, carcinogens, and mechanisms. Langenbecks Arch. Surg. 391(6), 603-613.

      Hoffmann, D., Djordjevic M.V., and Hoffmann, I. 1997. The changing cigarette. Prev. Med. 26(4), 427-434.

      International Agency for Research on Cancer (IARC). 1985. Tobacco Smoking. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vol. 38. International Agency for Research on Cancer, Lyon, France.

      International Organization for Standardization (ISO). 1991. International Standard ISO 3308, Routine Analytical Cigarette-Smoking Machine – Definitions and Standard Conditions. International Organization for Standardization, Geneva, Switzerland.

      International Organization for Standardization (ISO). 1999. International Standard ISO 3402, Tobacco and Tobacco Products – Atmosphere for Conditioning and Testing. International Organization for Standardization, Geneva, Switzerland.

      International Organization for Standardization (ISO). 2000. International Standard ISO 10315, Cigarettes Determination of Nicotine in Smoke Condensates – Gas-chromatographic Method. International Organization for Standardization, Geneva, Switzerland.

      International Organization for Standardization (ISO). 2006. International Standard ISO 8243, Cigarettes – Sampling. International Organization for Standardization, Geneva, Switzerland.

      International Organization for Standardization (ISO). 2007. International Standard ISO 8454, Cigarettes – Determination of Carbon Monoxide in the Vapour Phase of Cigarette Smoke – NDIR Method. International Organization for Standardization, Geneva, Switzerland.

      International Organization for Standardization (ISO). 2000. International Standard ISO 4387, Cigarettes – Determination of total and nicotine-free dry particulate matter using a routine analytical smoking machine. International Organization for Standardization, Geneva, Switzerland.

      Pankow, J.F., Watanabe, K.H., Toccalino, P.L., Luo, W., and Austin, D.F. 2007. Calculated cancer risks for conventional and “potentially reduced exposure product” cigarettes. Cancer Epidemiol. Biomarkers Prev. 16(3), 584-592.

      Penn, A., Batastini, G., Soloman, J., Burns, F., and Albert, R. 1981. Dose-dependent size increases of aortic lesions following chronic exposure to 7,12-dimethylbenz[a]anthracene. Cancer Res. 41(2), 588-592.

      Penn, A., and Snyder, C.A. 1996. Butadiene inhalation accelerates arteriosclerotic plaque development in cockerels. Toxicology 113(1-3), 351-354.

      Pryor, W.A. 1997. Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ. Health Perspect. 105(Suppl. 4), 875-882.

      Rodgman, A., and Green, C.R. 2003. Toxic chemicals in cigarette mainstream smoke – hazard and hoopla. Beit. Tabakforsch. Int. 20(8), 481-545.

      Rodgman, A., and Perfetti, T.A. 2013. The Chemical Components of Tobacco and Tobacco Smoke. 2nd Edition. CRC Press, Boca Raton.

      Roemer, E., and Carchmann, R.A. 2011. Limitations of cigarette machine smoking regimens. Toxicol. Lett. 203(1), 20-27.

      Smith, L.E., Denissenko, M.F., Bennett, W.P., Li, H., Amin, S., Tang, M., and Pfeifer, G.P. 2000. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J. Natl. Cancer Inst. 92(10), 803-811.

      Smith, C.J., and Hansch, C. 2000. The relative toxicity of compounds in mainstream cigarette smoke. Food Chem. Toxicol. 38(7), 637-646.

      Stratton, K., Shetty, P., Wallace, R., and Bondurant, S. 2001. Clearing the smoke. Assessing the science base for tobacco harm reduction. National Academy Press. Washington D.C.

      Talhout, R., Schulz, T., Florek, E., van Benthem, J., Wester, P., Opperhuizen, A. 2011. Hazardous compounds in tobacco smoke. Int. J. Environ. Res. Public Health 8(2), 613-628.

      U.S. Consumer Product Safety Commission (US CPSC). 1993. Toxicity Testing Plan for Low Ignition-Potential Cigarettes, vol. 5, part 1. US CPS, Washington, DC.

      U.S. Food and Drug Administration, 2012a. Harmful and potentially harmful constituents in tobacco products and tobacco smoke; established list. Fed. Register 77(64), 20034-20037.

      U.S. Food and Drug Administration, 2012b. Guidance for Industry. Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act. Draft Guidance. U.S. Department of Health and Human Services, Food and Drug Administration Center for Tobacco Products (CTP). Available here (Accessed 28.02.2023).

      Valavanidis, A., Vlachogianni, T., and Fiotakis, K. 2009. Tobacco smoke; Involvement of reactive oxygen species and stable free radicals in mechanisms of oxidative damage, carcinogenesis and synergistic effects with other respirable particles. Int. J. Environ. Res. Public Health 6(2), 445-462.

      Vineis, P., and Pirastu, R. 1997. Aromatic amines and cancer. Cancer Causes Control 8(3), 346-355.

      Vorhees, D.J., and Dodson, R.E. 1999. Estimating risk to cigarette smokers from smoke constituents in proposed “Testing and Reporting of Constituents of Cigarette Smoke" Regulations. Menzie-Cura & Associates, Inc.

      Witschi, H., Espiritu, I., Maronpot, R.R., Pinkerton, K.E., and Jones, D.A. 1997. The carcinogenic potential of the gas phase of environmental tobacco smoke. Carcinogenesis 18(11), 2035-2042.

      World Health Organization, 2007. The scientific basis of tobacco product regulation. Report of a WHO Study Group. WHO Technical Report Series 945. World Health Organization, Geneva, Switzerland.

      World Health Organization, 2008. The scientific basis of tobacco product regulation: Second report of a WHO Study Group. Technical Report Series 951, World Health Organization, Geneva, Switzerland.

      World Health Organization, 2012. World Health Organization Tobacco Laboratory Network. SOP 01 Standard operating procedure for intense smoking of cigarettes. World Health Organization, Geneva, Switzerland. Available here (accessed 28.02.2023)

      World Health Organization, 2015. WHO Study Group on Tobacco Product Regulation: Report on the Scientific Basis of Tobacco Product Regulations. Fifth Report of a WHO Study Group. Technical Report Series 989. World Health Organization, Geneva, Switzerland.

      Wright, C. 2015. Standardized methods for the regulation of cigarette-smoke constituents. Trends Anal. Chem. 66, 118-127.

      Xie, J., Marano, K.M., Wilson, C.L., Liu, H., Gan, H., Xie, F., and Naufal, Z.S. 2012. A probabilistic risk assessment approach used to prioritize chemical constituents in mainstream smoke of cigarettes sold in China. Regul. Toxicol. Pharmacol. 62(2), 355-362.

      Related Articles
      FDA's list of HPHCs
      See the levels of toxicants in THS aerosol compared with cigarette smoke according to the FDA-93 list.
      Tobacco Heating System mainstream aerosol compared with reference cigarette smoke
      We observed an average of 90-95% reduction of the levels of HPHCs in the THS aerosol.
      Tobacco Heating System
      We have developed several variants of the Tobacco Heating System (THS). These blade and induction devices heat rather than burn tobacco.​

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.